euro adhoc: Sartorius AG / quarterly or semiannual financial statement / Figures for the First Quarter of 2008 Sales revenue rose 3.8% (currency-adjusted: up 7.7%) | Currency-adjusted order intake

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

22.04.2008

To ensure the best possible comparability, the first-quarter figures
of 2007 are shown on a pro forma basis and adjusted for extraordinary
expenses.

Within the first three months of 2008, the Sartorius Group increased
sales revenue by 3.8% to EUR149.2 million (Q1 2007: EUR143.6 mn).
Currency-adjusted consolidated sales revenue climbed 7.7%. The
Biotechnology Division's sales revenue rose 5.4% (currency-adjusted:
+9.5%) to EUR90.6 (Q1 2007: EUR85.9 mn). Sales revenue for the
Mechatronics Division grew 1.5% (currency-adjusted: +5.1%) to EUR58.6
million (Q1 2007: EUR57.7 mn).

At EUR162.5 million, order intake was higher than sales revenue and
thus at the high level of the year-earlier quarter (EUR162.9 mn). On
the basis of constant currencies, order intake rose 3.4%. The
difference between sales revenue and order intake essentially
resulted from the fluctuations in the equipment business of the
Biotechnology Division. The Division's order intake was EUR97.6
million (Q1 2007: EUR99.1 million), which corresponds to a decline of
1.5% or a currency-adjusted increase of 2.2%. The value of orders for
the Mechatronics Division rose 1.8% or by a currency-adjusted rate of
5.3%.

First-quarter operating earnings (earnings before interest, taxes and
amortization = EBITA) increased from EUR11.8 million to EUR12.2
million. At 8.2%, the EBITA margin remained unchanged compared to the
year-earlier figure. If the EBITA margin had been calculated based on
the previous year's exchange rates, it would have increased to more
than 9%. EBITA for the Biotechnology Division rose from EUR8.4
million to EUR9.1; for the Mechatronics Division, EBITA at EUR3.1
million was below the year-earlier figure of EUR3.4 million. Net
profit after minority interest was EUR3.2 million (Q1 2007: EUR3.5
million); earnings per share (excluding the two non-cash items of
amortization and interest on share price warrants granted) were
EUR0.25 (Q1 2007: EUR0.26).

For the full fiscal year of 2008, the Sartorius Group is continuing
to aim at achieving sales revenue growth of more than 9% in constant
currencies. Based on this anticipated sales revenue and on an average
exchange rate of 1.40 USD/EUR, the Group is planning to increase the
EBITA margin to approx. 12%.

|EUR in millions |Q1 2008 |Q1 2007 |Change |
|(unless otherwise specified) | |pro forma |in % |
| | | | |
|Sartorius Group | | | |
|Sales revenue |149.2 |143.6 |+3.8 (+7.7)|
|Order intake |162.5 |162.9 |-0.2 (+3.4)|
|EBITA 1) |12.2 |11.8 |+3.7 |
|Net profit for the period 1)2) |4.2 |4.4 |-2.9 |
|Earnings per share 1)2) in EUR |0.25 |0.26 |-2.9 |
| | | | |
|Biotechnology Division | | | |
|Sales revenue |90.6 |85.9 |+5.4 (+9.5)|
|Order intake |97.6 |99.1 |-1.5 (+2.2)|
|EBITA 1) |9.1 |8.4 |+8.5 |
| | | | |
|Mechatronics Division | | | |
|Sales revenue |58.6 |57.7 |+1.5 (+5.1)|
|Order intake |64.9 |63.8 |+1.8 (+5.3)|
|EBITA 1) |3.1 |3.4 |-7.9 |

in parentheses: currency-adjusted 1) for 2007 underlying 2) excluding
non-cash amortization and, for 2008, additionally excluding non-cash
interest expenses for share price warrants

Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the quarterly
results for Sartorius with analysts and investors in a teleconference
at 4:30 p.m. CET following today's Annual Shareholder Meeting. You
may dial into this teleconference starting at 4:15 p.m. CET at the
following numbers:

Germany: +49 (0)69 5007 1316;
France: +33 (0)1 70 99 42 99;
UK: +44 (0)20 7806 1968;
USA: +1 718 354 1387.

The dial-in code is 3601455;

to view the webcast, log onto www.livemeeting.com/cc/premconfeurope/j
oin?id=3601455&role=attend&pw=pw7076

-----------------------

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Andreas Wiederhold

Treasury & Investor Relations

Telefon: +49 (0)551 308-1668

E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade